


Decade of Vaccine Global Vaccine Action Plan Independent review of progress and reporting to governing bodies

P. Duclos, WHO



**World Health
Organization**

Proposed Reporting Cycle at the Global Level



SAGE Working Groups



World Health
Organization

20, AVENUE APPY - CH 1211 GENEVA 27 - SWITZERLAND - TEL CENTRAL +41 22 791 2111 - FAX CENTRAL +41 22 791 3111 - WWW.WHO.INT

Purpose, structure and functioning of the Strategic Advisory Group of Experts on Immunization (SAGE) Working Groups

Purpose and decision to establish SAGE Working Groups

SAGE Working Groups are established as resources intended to increase the effectiveness of SAGE deliberations and providing evidence-based information and options for recommendations to be discussed by the full SAGE in an open public forum.

SAGE Working Group on influenza vaccines and immunization (established August 2010)

TERMS OF REFERENCE

Objectives of the Working Group:

1. Prepare for a SAGE evidence-based review and updating of WHO recommendations of seasonal influenza vaccine (e.g. priority target groups) with a particular focus on middle-income countries and with a view to update the 2005 WHO influenza vaccine position papers.
2. Prepare for a SAGE discussion on coverage goals for seasonal influenza vaccine proposed to the WHA to update the coverage goals contained in the 2003 recommendations.
3. Identify essential gaps in evidence that may impede SAGE's ability to update recommendations on the use of influenza vaccines and propose coverage target recommendations.
4. Provide advice about pandemic vaccine preparedness.

COMPOSITION

SAGE Members

- Elizabeth Miller, Chair
- Jon Abramson
- Claire-Anne Siegrist

Experts

- William Kwabena Ampofo, Noguchi Memorial Institute for Medical Research, Ghana
- Joseph Bresee, Centers of Disease Control, United States of America
- Janet Englund, Seattle Children's Hospital, United States of America
- Randeep Guleria, All India Institute of Medical Sciences, India
- Yu Hongjie, Chinese Center for Disease Control and Prevention, People's Republic of China
- Michael Pfeleiderer, Paul-Ehrlich-Institut, Germany
- David Salisbury, Department of Health, United Kingdom
- Barry Schoub, National Institute for Communicable Diseases, South Africa

WHO Secretariat

- Marie-Paule Kieny
- Philippe Duclos
- Cuauhtémoc Ruiz-Matus
- Nahoko Shindo

DECLARATION OF INTERESTS FOR WHO EXPERTS

All Working Group members completed a declaration of interests. Four members reported relevant interests. All interests were assessed not to constitute a conflict of interest. It was concluded that all members could take part in full in all of the discussions. The reported relevant interests are summarized below:

Janet Englund:

- Her department received funding from MedImmune, Novartis, Adan BioCRYST and Sanofi Pasteur for conducting research on meningococcal vaccines, influenza vaccines and human studies.

- Purpose, structure and functioning of the SAGE working groups (Annex 3 of SAGE's ToRs pages 11-12 of Yellow Book)
- Establishment and ToRs decided by WHO and SAGE members
- Composition
 - Public call for nominations
 - Members serve in personal capacity
 - At least two SAGE members & additional experts
 - Declaration of interests
- To review evidence and prepare for fruitful discussions at SAGE when issue is complex
- Not allowed to make decisions or speak on behalf of SAGE
- Time limited

SAGE Working Group on the Decade of Vaccines'

Global Vaccine Action Plan: *Terms of reference*

Facilitate a yearly SAGE independent review of the implementation of the DoV GVAP and assessment of progress.

- **independently evaluate and document progress** towards each of the 6 GVAP Strategic Objectives and towards the achievement of the DoV Goals (2011-2020), using the GVAP Monitoring & Evaluation/Accountability Framework;
- **identify successes, challenges and areas where additional efforts or corrective actions** by countries, regions, partners, donor agencies or other parties, **are needed**;
- identify and **document best practices**;
- **prepare the GVAP implementation annual report** to be presented to SAGE, and thereafter, with SAGE inputs, submitted for discussion to the WHO January EB meeting, to the WHA and the independent Expert Review Group for the UN Secretary General's Global Strategy for Women's and Children's Health.

The WG should take a broad perspective, encompassing the general environment, including the health system context.

SAGE Working Group on the Decade of Vaccines'

Global Vaccine Action Plan: *Membership*

- 2 SAGE members and an additional 8 experts **all serving in their individual capacity.**
- Chaired by a SAGE member (Chair will remain Chair even after he/she rotates out of SAGE).
- Following an **open call for nominations**, selection of the non-SAGE member experts by consensus by the DoV lead agencies (WHO, UNICEF, GAVI Alliance, Bill & Melinda Gates Foundation and National Institute of Allergy and Infectious Diseases (part of the National Institutes of Health U.S.) and a representative from the Civil Society Organizations (CSOs).
- Expertise relevant to the GVAP Goals and 6 Strategic Objectives
- Broad geographic representation, gender balance, and representation of a broad range of stakeholders and constituencies.

SAGE Working Group on the Decade of Vaccines'

Global Vaccine Action Plan: *Mode of operation and secretarial support (1 of 2)*

- Operation under the rules of functioning for SAGE Working Groups.
- Annual face-to-face meeting in September and reporting at subsequent November SAGE meeting.
- Additional teleconferences will be arranged on an ad-hoc basis to prepare for meetings.
- The Secretariat will facilitate the preparation of the reports to be reviewed by SAGE. Main administrative and secretariat support will be provided by WHO.

SAGE Working Group on the Decade of Vaccines' Global Vaccine Action Plan: *Mode of operation and secretarial support (2 of 2)*

Proceedings will be informed by:

- Annual monitoring report of GVAP indicators and achievement of goals and targets.
- Narrative progress report for each of the GVAP 6 Strategic Objectives (SO6 only once every two years).
- Annual M&E / Accountability report with tracking of resources and commitments.
- Annual regional reports on the GVAP implementation themselves generated with input from the Regional Immunization Technical Advisory Groups
- Annual reports from key stakeholders such as civil society and industry

All due by mid-August



THANK YOU